Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant Help Center Crisis
Powered By
Real members of MyMyelomaTeam have posted questions and answers that support our community guidelines, and should not be taken as medical advice. Looking for the latest medically reviewed content by doctors and experts? Visit our resource section.

New Myeloma Therapies Help Patients Stay in Remission Longer

A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA

https://www.patientpower.info/video/multiple-my...

https://www.patientpower.info/video/multiple-myeloma/new-myeloma-therapies-help-patients-stay-in-remission-longer
https://www.patientpower.info/video/multiple-myeloma/new-myeloma-therapies-help-patients-stay-in-remission-longer
June 17, 2025
 · 
Reactions
MyMyelomaTeam

Recent advances in myeloma treatment have dramatically improved survival rates. From 1998 to 2018, the five-year survival rate increased from 35% to 58%, with current rates likely even higher thanks to cutting-edge treatments.

Several promising new therapies have emerged in 2024
- A combination of talquetamab, Show Full Answer

Recent advances in myeloma treatment have dramatically improved survival rates. From 1998 to 2018, the five-year survival rate increased from 35% to 58%, with current rates likely even higher thanks to cutting-edge treatments.

Several promising new therapies have emerged in 2024:
- A combination of talquetamab, daratumumab, and pomalidomide showed an 82% response rate in hard-to-treat cases
- Adding daratumumab to standard therapy helped more newly diagnosed patients achieve undetectable cancer levels
- CAR T-cell therapy (ciltacabtagene autoleucel) reduced death risk by 45% in certain patients These newer treatments are leading to deeper, longer-lasting remissions, with some patients achieving what researchers call a "practical cure" - where myeloma remains undetectable without requiring ongoing treatment. Clinical trials continue to investigate promising new drugs like iberdomide and megzidomide, offering hope for even better outcomes in the future.

June 17, 2025
A MyMyelomaTeam Member

The interaction between chemotherapy and NK cells is complex:
The effects of chemotherapy on NK cells are not uniform and can vary depending on the specific drugs used, the cancer type, and the individual patient's immune response.
In some cases, chemotherapy can be used in combination with NK cell-based immunotherapy, where chemotherapy is used to prepare the body for the infused NK cells or to enhance their activity by making tumor cells more susceptible to their cytotoxic effects, according to a study published by the National Institutes of Health (NIH).
For example, some clinical trials combine chemotherapy with lenalidomide, which can enhance NK cell function.
Therefore, the interplay between chemotherapy and NK cells is a dynamic process, with chemotherapy potentially affecting both NK cell numbers and their activity, but also potentially contributing to their efficacy when used in combination with other therapies

June 24, 2025
A MyMyelomaTeam Member

I have been in the DVRD (darzalex, velcade, Revlimid, Dexamethasone) treatment since April and my numbers have greatly improved. Here’s to hoping that continues 👍

June 17, 2025

Related Questions

View All

Has anyone with refractory MM achieved remission? How long has it been?

A MyMyelomaTeam Member asked a question 💭
Monticello, IA
March 24

What Is CRISPR, and How Is It Used for Multiple Myeloma?

A MyMyelomaTeam Member asked a question 💭
Lake Charles, LA
October 10, 2025

Can Natural or Alternative Therapies Help Manage Multiple Myeloma Symptoms?
How Long Can Remission Last in Multiple Myeloma? Longest, Average, and More
33% Stay Myeloma-Free 5 Years After CAR T-Cell Therapy